Spine Surgery for Adhesions in Patients Evaluated for Efficacy and Safety of MedicurtainⓇ (Pivotal Study)
Primary Purpose
Intervertebral Disc Disorder, Thoracic Intervertebral Disc Disorders, Thoracolumbar Intervertebral Disc Disorders
Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Medicurtain®
GUARDIX-SG®
Sponsored by
About this trial
This is an interventional prevention trial for Intervertebral Disc Disorder focused on measuring Medicurtain®, Sodium hyaluronate, Hydroxyethylstarch, Anti-adhesion barrier
Eligibility Criteria
Inclusion Criteria:
- Aged between 20 ~ 70 years old
- Subject who is reserved with surgery for single-level or unilateral herniated lumbar Intervertebral disc
- Subject who is scheduled for In Situ Decompression(laparoscopic hysterectomy)
- Subject who does not respond to non-surgical treatment for at least past 6 weeks or require emergency surgery due to neural paralysis or excruciating pain
- Subject or his or her legal representative who signed and informed consent
Exclusion Criteria:
- Subject with multi-level or far lateral herniated lumbar intervertebral disc
- Subject with degenerative spinal disease or scoliosis
- Subject requires spinal fusion surgery
- Subject with severe liver or kidney disease
- Subject with lymph fluid or blood coagulation disease or medicated with blood clotting drug.
- Subject on oral or non-oral anti-diabetic drug or hypoglycemic drug
- Subject with suppressed immunity or autoimmune disease
- Subject with severe systemic disease
- Subject with infectious disease or healing disorder that may prevent normal healing process after surgery.
- Subject contraindicated with MRI scanning.
- Pregnant or lactating women
- Subject participated in other clinical trial within 30 days prior to the trial
Subject justified not eligible to participate in the trial by Investigator
- Subject undergone previous spinal surgery
- Subject treated steroid epidural injection within 2 weeks or take oral steroid within 24 hours after surgery
- Subject medicated aspirin or non-steroid anti-inflammatory drug within 7 days after surgery
- Subject received myelogram or lumbar puncture within 24 hours after surgery
Sites / Locations
- Samsung Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
GUARDIX-SG®
Medicurtain®
Arm Description
Treat GUARDIX-SG 5ml prefilled syringe after surgery
Treat Medicurtain® 5ml prefilled syringe after surgery
Outcomes
Primary Outcome Measures
Comparison of the average score of total MRI scar score evaluated by the independent evaluator after 12 weeks of the index surgery.
The intervertebral disc is divided into 5 consecutive axial sections and these 5 levels are divided into quadrant. Degree of peridural fibrosis is scaled by scar grading scale in 0~4 point range. (Total 20 score system)
*Area of quadrant filled with scar: no scar = 0 point, 0%~25% = 1 point, 25%~50% = 2 point, 50%~75% = 3 point, 75%~100% = 4 point
Secondary Outcome Measures
Comparison of the highest score of total MRI scar score evaluated by the independent evaluator after 12 weeks of the index surgery.
The intervertebral disc is divided into 5 consecutive axial sections and these 5 levels are divided into quadrant. Degree of peridural fibrosis is scaled by scar grading scale in 0~4 point range. (Total 20 score system)
*Area of quadrant filled with scar: no scar = 0 point, 0%~25% = 1 point, 25%~50% = 2 point, 50%~75% = 3 point, 75%~100% = 4 point
Comparison of Oswestry Disability Index (ODI) final score for overall satisfaction with the surgery
The Oswestry Low Back Pain Disability Index (ODI) ODI Version 2.0 measure disability and quality of life in individuals with low back pain (LBP). It consists of questions related to Activities of Daily Living (ADLs) and pain, and is measured on a scale of 0-5 points for every 10 sections
Comparison of Visual Analog Scale (VAS) score for overall satisfaction with the surgery
The severity of pain was evaluated using a visual analogue scale (VAS). The participants were requested to put a line on the scale perpendicularly that matched to their pain intensity. VAS scores (0-100) represent the pain intensity as none, mild, moderate, or severe
Full Information
NCT ID
NCT04688281
First Posted
December 23, 2020
Last Updated
September 28, 2021
Sponsor
Shin Poong Pharmaceutical Co. Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT04688281
Brief Title
Spine Surgery for Adhesions in Patients Evaluated for Efficacy and Safety of MedicurtainⓇ (Pivotal Study)
Official Title
Spine Surgery for Adhesions in Patients Evaluated for Efficacy and Safety of MedicurtainⓇ Multicenter, Randomized, Evaluator-blind, Parallel-controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
October 11, 2011 (Actual)
Primary Completion Date
March 25, 2013 (Actual)
Study Completion Date
March 25, 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shin Poong Pharmaceutical Co. Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study was designed to evaluate the efficacy and safety of Medicurtain®, an antiadhesion barrier in patients who underwent In Situ Decompression for single level and unilateral herniated lumbar intervertebral disc. Subjects were randomly assigned either into Medicurtain® treatment group or control group. Adhesion formations between the two groups at 12 weeks after surgery were compared by using MRI-applied scar score, ODI (Oswestry Disability Index) and VAS.
Detailed Description
This study was multicenter, randomized, evaluator-blind, parallel-controlled trial. A subject aged between 20~70 years old who was reserved for In Situ Decompression for single level and unilateral herniated lumbar intervertebral disc considered to be eligible for study entry. Subject screening was conducted at Visit 1 (screening period) to determine study based on the results of the examination for the spine surgery. Subject who met the inclusion/exclusion criteria were randomly assigned into either the treatment and control group at Visit 2 (Baseline: 0day) and received the defined treatment according to the protocol.
Direct evaluation of the level of adhesion around surgical area was analyzed by measuring peridural fibrosis and scar score through MRI (Total MRI scar score). Jeffrey S. Ross et al. reported that in evaluating scar in disc region, MR has been used by many researchers and shows 96% accuracy in identifying scar in disc region. Also measuring the level of fibrosis in surgical wounds through MRI scar score has already been widely used in many large-scale studies and shows almost perfect conformity degree I inter-and intra-observer reading results.
Therefore based on literatures, this study measures the level of adhesion in surgical wounds through MRI scar score, which has been validated and widely used in similar studies. Using MRI 3 months after surgery, the level of scar in lumbar spinal column is evaluated. All MRI images should be evaluated by one radiologist unless the randomization of the treatment group and control group is revealed. Peridural fibrosis is evaluated on the improved and unimproved state of axial T1-weighted image contrast. In MR image evaluation, location of peridural fibrosis to 5 consecutive axial sections that are 4mm thick around the intervertebral disc is recorded; these 5 levels are divided into quadrant which are divided by 2 straight lines vertical to the center of thecal sac.
Degree of peridural fibrosis is scaled by scar grading scale in 0~4 point range according to the dimension of the quadrant filled with scar. Record the scar score of each quadrant of 5 levels (total of 20 grades-scar score method). The measured scar scores of the investigational device group and control device group are compared and evaluated with total of 20 scores on each quadrant of 5 levels (Total MRI score).
After 2 weeks (2 weeks±3days) of the index surgery, following tests were performed to evaluate the subject's condition and adverse events at before signing on the informed consent and after the surgery. The investigation device is composed of mainly Sodium Hyaluronate(HA) and Hydroxyethylstarch(HES) which were degraded in the liver and excreted from the kidney, therefore, it is included liver and kidney function test and blood coagulation test since abnormal function of blood coagulation can increase adhesion around the surgical wound area.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intervertebral Disc Disorder, Thoracic Intervertebral Disc Disorders, Thoracolumbar Intervertebral Disc Disorders, Lumbosacral Intervertebral Disc Disorders, Tissue Adhesion, Surgery-Induced
Keywords
Medicurtain®, Sodium hyaluronate, Hydroxyethylstarch, Anti-adhesion barrier
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
87 (Actual)
8. Arms, Groups, and Interventions
Arm Title
GUARDIX-SG®
Arm Type
Active Comparator
Arm Description
Treat GUARDIX-SG 5ml prefilled syringe after surgery
Arm Title
Medicurtain®
Arm Type
Experimental
Arm Description
Treat Medicurtain® 5ml prefilled syringe after surgery
Intervention Type
Device
Intervention Name(s)
Medicurtain®
Intervention Description
Medicurtain® 5ml prefilled syringe
Intervention Type
Device
Intervention Name(s)
GUARDIX-SG®
Intervention Description
GUARDIX-SG® 5ml prefilled syringe
Primary Outcome Measure Information:
Title
Comparison of the average score of total MRI scar score evaluated by the independent evaluator after 12 weeks of the index surgery.
Description
The intervertebral disc is divided into 5 consecutive axial sections and these 5 levels are divided into quadrant. Degree of peridural fibrosis is scaled by scar grading scale in 0~4 point range. (Total 20 score system)
*Area of quadrant filled with scar: no scar = 0 point, 0%~25% = 1 point, 25%~50% = 2 point, 50%~75% = 3 point, 75%~100% = 4 point
Time Frame
Week 12
Secondary Outcome Measure Information:
Title
Comparison of the highest score of total MRI scar score evaluated by the independent evaluator after 12 weeks of the index surgery.
Description
The intervertebral disc is divided into 5 consecutive axial sections and these 5 levels are divided into quadrant. Degree of peridural fibrosis is scaled by scar grading scale in 0~4 point range. (Total 20 score system)
*Area of quadrant filled with scar: no scar = 0 point, 0%~25% = 1 point, 25%~50% = 2 point, 50%~75% = 3 point, 75%~100% = 4 point
Time Frame
Week 12
Title
Comparison of Oswestry Disability Index (ODI) final score for overall satisfaction with the surgery
Description
The Oswestry Low Back Pain Disability Index (ODI) ODI Version 2.0 measure disability and quality of life in individuals with low back pain (LBP). It consists of questions related to Activities of Daily Living (ADLs) and pain, and is measured on a scale of 0-5 points for every 10 sections
Time Frame
Week 12
Title
Comparison of Visual Analog Scale (VAS) score for overall satisfaction with the surgery
Description
The severity of pain was evaluated using a visual analogue scale (VAS). The participants were requested to put a line on the scale perpendicularly that matched to their pain intensity. VAS scores (0-100) represent the pain intensity as none, mild, moderate, or severe
Time Frame
Week 12
Other Pre-specified Outcome Measures:
Title
The incidence rate of adverse events
Description
Safety and tolerability by collecting adverse events (AEs)
Time Frame
follow up to 12 weeks
Title
The incidence rate of treatment-emergent adverse event (TEAE)
Description
Safety and tolerability by collecting treatment-emergent adverse event (TEAE)
Time Frame
follow up to 12 weeks
Title
The incidence rate of adverse device event
Description
Safety and tolerability by collecting adverse device event (ADEs)
Time Frame
follow up to 12 weeks
Title
The incidence rate of serious adverse events
Description
Safety and tolerability by collecting serious adverse events (SAEs)
Time Frame
follow up to 12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Aged between 20 ~ 70 years old
Subject who is reserved with surgery for single-level or unilateral herniated lumbar Intervertebral disc
Subject who is scheduled for In Situ Decompression(laparoscopic hysterectomy)
Subject who does not respond to non-surgical treatment for at least past 6 weeks or require emergency surgery due to neural paralysis or excruciating pain
Subject or his or her legal representative who signed and informed consent
Exclusion Criteria:
Subject with multi-level or far lateral herniated lumbar intervertebral disc
Subject with degenerative spinal disease or scoliosis
Subject requires spinal fusion surgery
Subject with severe liver or kidney disease
Subject with lymph fluid or blood coagulation disease or medicated with blood clotting drug.
Subject on oral or non-oral anti-diabetic drug or hypoglycemic drug
Subject with suppressed immunity or autoimmune disease
Subject with severe systemic disease
Subject with infectious disease or healing disorder that may prevent normal healing process after surgery.
Subject contraindicated with MRI scanning.
Pregnant or lactating women
Subject participated in other clinical trial within 30 days prior to the trial
Subject justified not eligible to participate in the trial by Investigator
Subject undergone previous spinal surgery
Subject treated steroid epidural injection within 2 weeks or take oral steroid within 24 hours after surgery
Subject medicated aspirin or non-steroid anti-inflammatory drug within 7 days after surgery
Subject received myelogram or lumbar puncture within 24 hours after surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chong-Suh Lee, MD, PhD
Organizational Affiliation
Samsung Medical Center, Gangnam-gu, Ilwon-dong 50, Seoul, South Korea
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Eun-Sang Kim, MD, PhD
Organizational Affiliation
Samsung Medical Center, Gangnam-gu, Ilwon-dong 50, Seoul, South Korea
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ki-Tack Kim, MD, PhD
Organizational Affiliation
Kyung Hee University Hospital, Gangdong-gu, Sangil-dong 149, Seoul, South Korea
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Joomyung Kim, MD, PhD
Organizational Affiliation
Samsung Medical Center, Gangnam-gu, Ilwon-dong 50, Seoul, South Korea
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Yong Cheol Yoon, MD, PhD
Organizational Affiliation
Hallym University Medical Center, Pyeongchon-dong 896, Anyang, Gyeonggi-do, South Korea
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Bong-Soon Chang, MD, PhD
Organizational Affiliation
Seoul National University Hospital , Jongro-gu, Yeongeon-dong, Seoul, South Korea
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Byung-Joon Shin, MD, PhD
Organizational Affiliation
Soonchunhyang University Hospital , Yongsan-gu, Daesagwan-ro 59, Seoul, South Korea
Official's Role
Principal Investigator
Facility Information:
Facility Name
Samsung Medical Center
City
Seoul
State/Province
Gangnam-gu, Ilwon-dong 50
Country
Korea, Republic of
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Spine Surgery for Adhesions in Patients Evaluated for Efficacy and Safety of MedicurtainⓇ (Pivotal Study)
We'll reach out to this number within 24 hrs